Parameter
| Biomarker | Interleukin-6 (IL-6) | Full name | Interleukin-6 | Molecular Type | Proteins (proinflammatory cytokines) |
|---|---|---|---|---|---|
| Molecular Formula | Human IL-6: C₁₈₄H₂₈₇N₄₉O₅₇S | Molecular Weight | ~21 kDa | Core Functional Dimensions | Assessment of immune inflammatory activation |
| Disease | Inflammatory Bowel Disease (IBD) | Disease Subtypes | / | ||
| Organ | Intestine | Test Sample / Technology Platform | Serum/intestinal mucosal biopsy (ELISA, chemiluminescence, flow cytometry) | ||
| Pathobiological Mechanisms | 1. It is secreted by macrophages and intestinal epithelial cells and activates the JAK/STAT3 pathway to promote B cell differentiation and acute phase response protein synthesis; (2) The level of serum IL-6 in active stage of IBD is increased (CD patients median 18pg/mL, UC patients median 15pg/mL, healthy people < 5pg/mL), which is positively correlated with the degree of intestinal mucosal inflammatory infiltration; The level of IL-6 could predict the response rate of IBD patients to tofacitinib (JAK inhibitor) with a sensitivity of 76% | ||||
| Clinical Availability Status | Clinical routine auxiliary application | ||||
| Notes and Dynamics | (1) IL-6 combined with CRP could improve the predictive accuracy of anti-IL-23 treatment response in CD patients (AUC=0.81); (2) The phase Ⅱ clinical trial of a novel IL-6 receptor antagonist (PMX-60056) in UC in 2025 showed that the mucosal healing rate increased by 30% | ||||